1. Home
  2. TSLX vs PVLA Comparison

TSLX vs PVLA Comparison

Compare TSLX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

N/A

Current Price

$18.06

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

N/A

Current Price

$132.80

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSLX
PVLA
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
TSLX
PVLA
Price
$18.06
$132.80
Analyst Decision
Buy
Strong Buy
Analyst Count
11
15
Target Price
$19.77
★ $230.53
AVG Volume (30 Days)
★ 363.2K
144.1K
Earning Date
11-03-2026
11-10-2026
Dividend Yield
★ 9.82%
N/A
EPS Growth
N/A
★ 52.62
EPS
★ 0.15
N/A
Revenue
N/A
★ $42,810,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.99
N/A
P/E Ratio
$122.30
★ N/A
Revenue Growth
N/A
★ 65.28
52 Week Low
$16.04
$61.73
52 Week High
$23.19
$161.38

Technical Indicators

Market Signals
Indicator
TSLX
PVLA
Relative Strength Index (RSI) 46.69 35.76
Support Level $17.20 $135.68
Resistance Level $18.59 $159.84
Average True Range (ATR) 0.33 5.91
MACD -0.00 -1.95
Stochastic Oscillator 34.95 3.05

Price Performance

Historical Comparison
TSLX
PVLA

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: